老年弥漫大B细胞淋巴瘤预后的相关影响因素探讨

doi:10.3969/j.issn.1671-7171.2017.02.004

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To discuss the prognosis-related factors of elderly patients with diffuse large B-cell lymphoma (DLBCL). 【Methods】We retrospectively analyzed the clinical data from 70 cases of elderly patients with initial diffuse large B-cell lymphoma from January 2009 to December 2014. The parameters included gender, age, Ann-Arbor staging, B symptoms, ECOG score of performance status (ECOG-PS), serum level of lactate dehydrogenase (LDH), international prognostic index (IPI) and bone marrow invasion. We also compared the survival of patients who received CHOP chemotherapy and R-CHOP chemotherapy.The correlation between these indexes and prognosis was analyzed. 【Results】The median survival of all 70 cases of elderly patients with DLBCL was 41.67 months and the OS rate of 2 years was 69.2%. Single factor analysis showed that age, Ann-Arbor staging, bone marrow involvement, ECOG score, IPI score, value of LDH before treatment and therapeutic regimen were all related with prognosis (P<0.05 or P<0.01). COX regression multiple-factor analysis indicated that ECOG score、IPI score、bone marrow invasion and chemotherapy were the independent factors for predicting the prognosis of the elderly patients with DLBCL (P<0.01). 【Conclusion】ECOG score、IPI score、bone marrow invasion and chemotherapy were independent predictive and prognostic factors in elderly patients with DLBCL. R-CHOP chemotherapy has more advantages than CHOP chemotherapy in improving prognosis of elderly patients with DLBCL.

Key words： Lymphoma, Large B-Cell, Diffuse Prognosis Risk Factors Aged

Received: 18 January 2016

PACS:

R733.41

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHAO Shu-qing
	LI Jun-min
	XU Zi-zhen
	et al

Cite this article:

ZHAO Shu-qing,LI Jun-min,XU Zi-zhen, et al. Research on the Prognosis-related Factors of Elderly Patients with Diffuse Large B-cell Lymphoma[J]. JOURNAL OF CLINICAL RESEARCH, 2017, 34(2): 219-222,225.

URL:

http://www.jcr.net.cn/EN/10.3969/j.issn.1671-7171.2017.02.004 OR http://www.jcr.net.cn/EN/Y2017/V34/I2/219

[1] Latta S, Cygan PH, Fried W,et al. Diffuse large B-cell non-Hodgkin lymphoma in the very elderly: challenges and solutions[J].Oncology,2013, 27(2):126-132.
[2] Siegel R, MA J, ZOU Z, et al. Cancer statistics[J].CA Cancer J Clin,2014, 64(1):9-29.
[3] LI XQ,LI GD ,GAO ZF, et al. The relative frequencies of lymphoma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group[J].Ann Oncol,2011, 2(suppl4):141-142.
[4] Shi YF, Li XH, Song YQ, et al. Involvement of bone marrow in lymphoma: pathological investigation in a single-center from northern China[J].Int J Clin Exp Pathol,2015, 8(6):7102-7111.
[5] Sovani V, Harvey C, Haynes AP,et al.Bone marrow trephine biopsy involvement by lymphoma: review of histopathological features in 511 specimens and correlation with diagnostic biopsy, aspirate and peripheral blood findings[J].J Clin Pathol,2014, 67(5):389-395.
[6] 中华医学会血液学分会,中国抗癌协会淋巴瘤专业委员会. 中国弥漫大B细胞淋巴瘤诊断与治疗指南(2013年版)[J].中华血液学杂志, 2013, 34(9):816-819.
[7] Ciancia R, Tirelli U, Ribera J, et al. Management of elderly patients with diffuse large B-cell lymphomas[J].Anticancer Agents Med Chem,2013, 13(9):1412-1418. [8] Shipp MA,Harrington DP.A predictive model for aggressive non-hodgkin's lymphoma. the international non-hodgkin's lymphoma prognostic factors project[J].N Engl J Med,1993, 329(14):987-994.
[9] Ziepert M, Hasenclever D, Kuhnt E,et al.Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era[J].J Clin Oncol,2010, 28(14):2373-2378.
[10] Kim JS, Gang GW, Lee SR, et al.Bone marrow vascular endothelial growth factor level per platelet count might be a significant predictor for the treatment outcomes of patients with diffuse large B-cell lymphomas[J].Jpn J Clin Oncol,2015, 45(10):914-920.
[11] Morrison VA,Hamlin P,Soubeyran P,et al.Diffuse large B-cell lymphoma in the elderly: Impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology Expert Position Paper[J].J Geriatr Oncol,2015, 6(2):141-152.
[12] Feugier P, Van Hoof A, Sebban C,et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte[J].J Clin Oncol,2005, 23(18):4117-4126.
[13] Pfreundschuh M, Schubert J, Ziepert M,et al.Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)[J].Lancet Oncol,2008, 9(2):105-116.
[14] Delarue R, Tilly H, Mounier N,et al.Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial[J].Lancet Oncol,2013, 14(6):525-533.
[15] Williams JN, Rai A, Lipscomb J, et al. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma[J].Cancer,2015, 121(11):1800-1808.